Association Between Serum Myostatin Levels, Hospital Mortality, and Muscle Mass and Strength Following ST-Elevation Myocardial Infarction

• Published in: Heart, lung & circulation lung & circulation, 2022-03, Vol.31 (3), p.365-371
• Main Authors: Oliveira, Paula G.S., Schwed, Juliana F., Chiuso-Minicucci, Fernanda, Duarte, Sara R.S., Nascimento, Lucas M., Dorna, Mariana S., Costa, Nara A., Okoshi, Katashi, Okoshi, Marina P., Azevedo, Paula S., Polegato, Bertha F., Paiva, Sergio A.R., Zornoff, Leonardo A.M., Minicucci, Marcos F.
• Format: Article
• Language: English
• Subjects: Aged; Growth differentiation factor 8; Hand Strength; Hospital Mortality; Humans; Male; Middle Aged; Muscle mass; Muscles; Myocardial infarction; Myostatin; Prognosis; Risk Assessment; ST Elevation Myocardial Infarction - diagnosis
• ISSN: 1443-9506; 1444-2892
• DOI: 10.1016/j.hlc.2021.08.018

This study aimed to evaluate the association between serum myostatin levels, hospital mortality, and muscle mass and strength following ST-segment elevation myocardial infarction (STEMI). This was a prospective observational study. Within 48 hours of admission, bioelectrical impedance and handgrip strength were assessed and blood samples collected for myostatin evaluation. Hospital mortality was recorded. A multiple logistic regression model was also constructed, adjusted by parameters that exhibited significant differences in the univariate analysis, to evaluate the association between myostatin levels and hospital mortality. One hundred and two (102) patients were included: mean age was 60.5±10.6 years, 67.6% were male, and 6.9% died during hospital stay. Univariate analysis showed that patients with lower myostatin levels had higher mortality rates. Serum myostatin levels positively correlated with handgrip strength (r=0.355; p